ArticleEndocrine2026
"Acute-phase reactions to zoledronate in clinical practice: a prospective single center study of 1,150 patients."
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the frequency, type, and severity of acute-phase reaction (APR) following zoledronate (ZOL) infusion, identify associated clinical risk factors, and compare treatment-naïve patients with those receiving ZOL as sequential therapy. A secondary objective was to assess recall bias through a 90-day retest.
methodsA prospective study was conducted at a single bone clinic. Patients who received 5 mg ZOL were invited to complete questionnaires at 3 and 7 days post-infusion. Symptom frequency and severity were analyzed, and clinical factors were assessed using multivariate logistic regression. Symptoms with intensity ≥ 8 on a 0-10 Numerical Rating Scale (NRS) were considered severe.
resultsThe mean age of the 1,150 patients was 66.9 ± 8.5 years, 97% were women. At least one symptom was reported by 867 (75%) patients. The most common were general and musculoskeletal symptoms (61 and 58%), followed by gastrointestinal (23%), ocular (13%), and fever (8%). Severe symptoms were reported by 22%. While 94% expressed willingness to repeat treatment, severe symptoms were significantly associated with treatment decline: 68% of those who declined versus 19% among those willing to continue (p < 0.001). A 90-day retest revealed systematic under-recall of mild general, musculoskeletal, and gastrointestinal symptoms (McNemar p < 0.05), whereas fever, ocular, and severe symptoms remained stable over time. First-time infusion was significantly associated with all symptoms and severity, whereas older age predicted a lower risk of general, gastrointestinal, fever, and severe symptoms. Among first-infusion patients (n = 704), prior bisphosphonate was associated with a reduced frequency and severity of symptoms. Preventive analgesics were associated with lower risk of general and musculoskeletal symptoms.
conclusionThis real-life study shows a high frequency of APR when symptoms are assessed shortly after ZOL infusion with mild symptoms systematically underestimated over time. First infusion, younger age, and lack of prior bisphosphonate exposure were the main risk factors identified. These findings support improving pre-infusion counseling in higher-risk patients to reduce anxiety and support long-term adherence to osteoporosis treatment.
Indexed as
Identifiers
42573909What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.